1-3 of 3
Gwen Kurilik
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia Patients.

Richard D. Press, MD, PhD, Zac Love, Ashlie A. Tronnes, Gwen Kurilik, Michael J. Mauro, MD, Michael W. Deininger, MD, PhD, Brian J. Druker, MD
Journal: Blood
Blood (2004) 104 (11): 1098.
https://doi.org/10.1182/blood.V104.11.1098.1098
Published: 2004
Journal Articles

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

Clinical Trials & Observations
Michael E. O'Dwyer, Michael J. Mauro, Carolyn Blasdel, Melanie Farnsworth, Gwen Kurilik, Yi-Ching Hsieh, Motomi Mori, Brian J. Druker
Journal: Blood
Blood (2004) 103 (2): 451–455.
https://doi.org/10.1182/blood-2003-02-0371
Published: 2004
Journal Articles

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

Clinical Trials & Observations
Michael E. O'Dwyer, Michael J. Mauro, Gwen Kurilik, Motomi Mori, Suzanne Balleisen, Susan Olson, Ellen Magenis, Renaud Capdeville, Brian J. Druker
Journal: Blood
Blood (2002) 100 (5): 1628–1633.
https://doi.org/10.1182/blood-2002-03-0777
Published: 2002